Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients
| Autor: | J. Razumny, Marta Barontini, I. Molocznik, A. Kleiman, A. M. Mancini, Ines Armando, Gloria Levin |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
Pituitary gland medicine.medical_specialty Adolescent Epinephrine Dopamine Endocrinology Diabetes and Metabolism Receptors Dopamine Norepinephrine Catecholamines Endocrinology Internal medicine medicine Humans Pituitary Neoplasms Bromocriptine Prolactinoma business.industry Dopaminergic medicine.disease Prolactin medicine.anatomical_structure Catecholamine Female business medicine.drug |
| Zdroj: | Journal of Endocrinological Investigation. 9:223-226 |
| ISSN: | 1720-8386 0391-4097 |
| DOI: | 10.1007/bf03348104 |
| Popis: | The effect of short term bromocriptine (5 mg/day, 5 days) on plasma epinephrine (E), norepinephrine (NE), dopamine (DA) and prolactin (PRL) was studied in 4 normal women and 6 bearing PRL-secreting tumors. When studied on placebo no significant differences were found between controls and patients in E, NE and DA plasma levels. Bromocriptine induced: a) a 70% decrease in PRL levels in both groups, b) a significant (p < 0.05) decrease in plasma NE levels in the control group, c) no significant change in plasma NE levels in the hyperprolactinemic patients when considered as a group. These results do not indicate that bromocriptine is a useful tool in the diagnosis of defective central dopaminergic regulation since individual responses of the PRL-secreting tumor patients were variable. Nevertheless, the impaired response of the group as a whole may be suggesting an underlying alteration of DA2 receptor activity in these tumor patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink